ArticlePloS one2024
Performance of three diagnostic tests for tuberculosis among Human Immunodeficiency Virus (HIV) patients presenting to a health facility in an informal urban settlement in Nairobi, Kenya.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The absence of an accurate reference test complicates the evaluation of tuberculosis (TB) diagnostic tests among people living with Human Immunodeficiency Virus (PLWHIV). The objective of this study was to estimate (using Bayesian latent class models [BLCM]) the sensitivity (Se), specificity (Sp) and negative and positive predictive values (NPV and PPV) of sputum smear microscopy (SSM), Xpert Ultra and lipoarabinomannan antigen (LAM) tests for TB among PLWHIV in Nairobi, Kenya. This cross-sectional study enrolled a total of 190 patients aged ≥ 18 years with presumptive TB seeking treatment at the Kibra Community Health Center Comprehensive Care Centre (CCC) clinic between September 2022 and March 2023. The diagnostic data obtained from the three tests were analysed using a BLCM framework to derive accuracy estimates of the three diagnostic tests. The Xpert Ultra assay registered a higher Se (85.0; 95% PCI [41.4-99.4]) compared to LAM (26.8; 95% PCI [4.7-67.6]) and SSM (56.7 [16.4-97.4]). However, SSM had the highest Sp (99.6; 95% PCI [97.7-100.0]). The Xpert Ultra assay yielded the highest overall combination of Se and Sp at 80.8% (95% PCI [37.0-96.5]). On predictive values, SSM recorded the highest PPV at 84.5% (95% PCI [38.4-99.4]). Nonetheless, all the tests exhibited noticeably high NPVs (>96%). The Xpert Ultra assay recorded the highest Se of the three tests. Nevertheless, the SSM test registered the highest Sp and correspondingly the highest PPV. On NPVs, the tests had similar estimates. Consequently, a two-test serial testing strategy, entailing an initial screening with the more sensitive Xpert Ultra assay followed by retesting of any positives with the more specific SSM test, could be most optimal in this low-burden TB setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.